Assessment of efficacy and safety of UV-based therapy for psoriasis: a network meta-analysis of randomized controlled trials

Figures & data

Figure 1. Structure of network formed by interventions. The lines between treatment nodes indicate the direct comparisons made within randomized controlled trials. The solid line means direct comparisons and the dashed line means indirect comparisons. (A) Main network meta-analysis. (B) Subgroup analysis.

Table 1. Detailed results of main network analysis.

Treatment	RR (95% CI) for PASI 75 response	SUCRA for PASI 75 response, %	RR (95% CI) for PASI 75 and above response	SUCRA for PASI 75 and above response, %	SMD (95% CI) for absolute PASI improvement	SUCRA for absolute PASI improvement, %	RR (95% CI) for withdrawal due to AEs	SUCRA for withdrawal due to AEs, %	RR (95%CI) for incidence of erythema	SUCRA for incidence of erythema, %
PUVA	1.06 (0.65, 1.71)	26.9	0.94 (0.66, 1.34)	23.5	1.41 (−2.13, 4.96)	19.4	Reference	46.6	Reference	39.1
UVB	1.09 (0.63, 1.88)	32.0	0.94 (0.64, 1.38)	23.3	0.46 (−3.02, 3.95)	23.3	0.95 (0.34, 2.68)	49.3	0.89 (0.69, 1.16)	65.8
cPUVA	1.47 (0.82, 2.64)	86.0	1.15 (0.77, 1.73)	81.1	−0.76 (−4.10, 2.58)	89.5	1.00 (0.29, 3.51)	46.7	0.95 (0.59, 1.52)	52.6
cUVB	1.38 (0.77, 2.47)	79.0	1.13 (0.76, 1.68)	78.4	−0.89 (−3.93, 2.15)	67.4	0.87 (0.23, 3.31)	54.9	0.90 (0.61, 1.32)	61.0
cAB	Reference	26.1	Reference	43.8	Reference	50.4	0.83 (0.02, 41.33)	52.5	1.20 (0.44, 3.25)	31.5

Table 2. The league plots of main network meta-analysis (from the top left to the bottom right, higher comparator vs. lower comparator).

a. PASI 75 and above response (lower left) and PASI 75 response (upper right), RR with 95% CI.
cPUVA	0.94 (0.64–1.38)	0.74 (0.51–1.07)	0.72 (0.52–1.00)	0.68 (0.38–1.22)
1.02 (0.79–1.31)	cUVB	0.79 (0.64–0.97)	0.77 (0.55–1.06)	0.72 (0.40–1.30)
1.22 (0.97–1.55)	1.20 (1.06–1.37)	UVB	0.97 (0.75–1.26)	0.92 (0.53–1.59)
1.23 (1.01–1.50)	1.20 (0.99–1.46)	1.00 (0.87–1.15)	PUVA	0.94 (0.58–1.53)
1.15 (0.77–1.73)	1.13 (0.76–1.68)	0.94 (0.64–1.38)	0.94 (0.66–1.34)	cAB
b. Absolute PASI improvement (lower left), SMD with 95% CI.
cPUVA
0.95 (−1.11–3.01)	cUVB	–	–	–
2.17 (0.15–4.18)	1.22 (0.05–2.39)	UVB	–	–
2.31 (0.48–4.13)	1.35 (−0.35–3.06)	0.14 (−1.25–1.52)	PUVA	–
1.41 (−2.13–4.96)	0.46 (−3.02–3.95)	−0.76 (−4.10–2.58)	−0.89 (−3.93–2.15)	cAB
c. Withdrawal due to AEs (lower left) and incidence of erythema (upper right), RR with 95% CI.
cUVB	1.05 (0.61–1.80)	1.33 (0.46–3.87)	0.99 (0.74–1.34)	1.11 (0.75–1.63)
0.87 (0.15–4.89)	cPUVA	1.27 (0.42–3.83)	0.95 (0.57–1.57)	1.06 (0.66–1.70)
1.05 (0.02–65.78)	1.21 (0.02–73.81)	cAB	0.75 (0.27–2.09)	0.83 (0.31–2.26)
0.91 (0.37–2.26)	1.05 (0.22–5.00)	0.87 (0.02–49.62)	UVB	1.12 (0.86–1.45)
0.87 (0.23–3.31)	1.00 (0.29–3.51)	0.83 (0.02–41.33)	0.95 (0.34–2.68)	PUVA

Figure 2. Forest plots incorporated direct comparisons and indirect comparisons of main network meta-analysis. (1) PASI 75 response. (2) PASI 75 and above response. (3) Absolute PASI improvement. (4) Withdrawal due to AEs. (5) Incidence of erythema. (A: PUVA; B: UVB; C: cPUVA; D: cUVB; E: cAB).

Figure 3. Forest plots of network comparisons of main network meta-analysis. (1) PASI 75 response. (2) PASI 75 and above response. (3) Absolute PASI improvement. (4) Withdrawal due to AEs. (5) Incidence of erythema.

Table 3. Detailed results of subgroup analysis.

Treatment	RR (95% CI) for PASI 75 response	SUCRA for PASI 75 response, %	RR (95% CI) for PASI 75 and above response	SUCRA for PASI 75 and above response, %	SMD (95% CI) for absolute PASI improvement	SUCRA for absolute PASI improvement, %	RR (95% CI) for withdrawal due to AEs	SUCRA for withdrawal due to AEs, %	RR (95% CI) for incidence of erythema	SUCRA for incidence of erythema, %
PUVA	1.00 (0.79, 1.28)	26.5	1.01 (0.88, 1.15)	21.1	0.07 (-0.70,0.83)	22.5	0.92 (0.49,1.73)	46.7	0.92 (0.49,1.73)	43.6
UVB	Reference	24.8	Reference	18.2	Reference	18.6	0.80 (0.41,1.57)	48.6	0.80 (0.41,1.57)	62.7
PAVA	1.14 (0.73, 1.78)	45.4	1.11 (0.87, 1.41)	45.1	0.73 (−0.63, 2.09)	49.4	Reference	32.2	Reference	39.8
PAVD	1.87 (1.09, 3.19)	91.5	1.88 (1.21, 2.92)	97.4	4.97 (3.12, 6.82)	98.3	0.98 (0.30, 3.17)	80.8	0.98 (0.30, 3.17)	44.1
UBVA	1.19 (0.75, 1.89)	51.5	1.21 (0.89, 1.64)	60.2	0.67 (−0.43, 1.77)	48.3	1.37 (0.57, 3.33)	40.4	1.37 (0.57, 3.33)	23.2
UBVD	1.04 (0.73, 1.48)	34.0	1.19 (0.96, 1.49)	60.2	0.13 (−1.47, 1.73)	27.9	0.58 (0.23, 1.46)	42.8	0.58 (0.23, 1.46)	83.6
UBST	1.58 (1.08, 2.31)	83.0	1.26 (1.01, 1.57)	70.8	0.51 (−0.66, 1.68)	42.6	0.68 (0.21, 2.15)	65.3	0.68 (0.21, 2.15)	68.3
UBSL	1.21 (0.81, 1.80)	54.4	1.09 (0.87, 1.37)	41.5	3.60 (2.03, 5.18)	88.9	0.88 (0.40, 1.92)	42.8	0.88 (0.40, 1.92)	49.3
cAB	1.08 (0.69, 1.69)	39.0	1.05 (0.74, 1.50)	35.4	0.96 (−0.93, 2.85)	53.5	1.11 (0.34, 3.57)	50.5	1.11 (0.34, 3.57)	35.2

Data availability statement

Data generated or analysed during this study are included in this published article. The datasets generated during and/or analysed during this study are available from the corresponding author on reasonable request.